# Loteprednol Etabonate Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

> **NCT02208297** · PHASE3 · COMPLETED · sponsor: **Bausch & Lomb Incorporated** · enrollment: 326 (actual)

## Conditions studied

- Inflammation
- Pain
- Cataract

## Interventions

- **DRUG:** Loteprednol Etabonate Gel (BID)
- **DRUG:** Vehicle Gel (BID)

## Key facts

- **NCT ID:** NCT02208297
- **Lead sponsor:** Bausch & Lomb Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 326 (ACTUAL)
- **Last updated:** 2020-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02208297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02208297, "Loteprednol Etabonate Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02208297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*